摘要
目的探讨α-干扰素联合拉米夫定治疗慢性乙型肝炎对HBV YMDD变异的影响。方法将50例患者随机分为治疗组30例,给予口服拉米夫定100 mg/d,同时予以α1b-干扰素5 MU/d,肌肉注射,2周后改为隔日1次,疗程为1年;对照组20例,单用拉米夫定100 mg/d,疗程为1年。结果疗程结束时两组患者HBV YMDD变异率分别为10.0%和30.0%(P<0.05),HBeAg血清转换率分别为40.0%和35.0%(P>0.05)。治疗组YMDD变异的发生率明显低于对照组。结论拉米夫定联合α-干扰素治疗慢性乙型肝炎不能提高HBeAg血清转换率,但可降低YMDD变异率。
Objective To investigate the effect of lamivudine combined with α-interferon on variation of HBV YMDD in treatment of chronic hepatitis B.Methods Fifty patients were randomly divided into two groups.Treatment group（30 cases） was given oral lamivudine 100 mg/d,at the same time was given α1b-interferon 5 MU/d,intramuscular injection,once two days two weeks later,the course was one year.Control group of 20 cases,was given lamivudine 100 mg/d only,course of treatment for a period of one year.Results HBV YMDD rate were 10.0% and 30.0%（P0.05） of the two groups.HBeAg serum conversion rate were 40.0 % and 35.0%（P0.05）.The variation rate of HBV YMDD in treatment group was significantly lower than that in control group.Conclusion Lamivudine combined with α-interferon in treatment of chronic hepatitis,do not improve HBeAg serum conversion rate,but can reduce the variation rate of YMDD.
出处
《临床医学》
CAS
2010年第12期24-25,共2页
Clinical Medicine
